Abstract. The Wnt/β-catenin signaling pathway has been reported to regulate cisplatin resistance in several types of cancer cell. The present study aimed to investigate the role and underlying mechanism of Wnt/β-catenin signaling in cisplatin resistance of lung adenocarcinoma cells. Wild-type and cisplatin-resistant A549 human lung adenocarcinoma cells (A549/WT and A549/CDDP, respectively) were cultured in vitro and exposed to different cisplatin concentrations. Cells were incubated with 10 mM lithium chloride (LiCl) to activate β-catenin signaling. Cell proliferation was determined using the MTS assay. Cell apoptosis was evaluated using Annexin V/propidium iodide double staining, followed by flow cytometry. β-catenin was knocked down using small interfering RNA (siRNA). The intracellular distribution of β-catenin was determined by immunocytochemistry, and the mRNA and protein expressions of target genes were examined by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. β-catenin and B-cell lymphoma-extra large (Bcl-xl) were significantly upregulated in A549/CDDP cells compared with A549/WT cells (P<0.05). LiCl reduced the sensitivity of A549/WT cells to cisplatin (P<0.01); and upregulated, increased phosphorylation (P<0.05) and enhanced nuclear translocation of β-catenin. LiCl also significantly elevated the mRNA and protein expression levels of Bcl-xl (P<0.05). Notably, silencing of β-catenin with siRNA decreased the mRNA and protein expression of Bcl-xl, and sensitized A549/WT cells to cisplatin (P<0.01). The findings of the current study suggest that upregulation of β-catenin signaling may contribute to cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl. Therefore, molecular targeting of Wnt/β-catenin signaling may sensitize lung cancer cells to cisplatin.
Introduction
Lung cancer is the leading cause of cancer-associated mortality worldwide, with an age-standardized world incidence rate of 44.7 for males and 19.6 for females per 100,000, and an age-standardized world mortality rate of 36.8 for males and 14.3 for females per 100,000 in more developed areas (1) . In the past decade, great advances have been made in the treatment of lung cancer using surgery, chemotherapy and radiotherapy; however, the five-year survival rate is still low (2) . The majority of patients with cancer develop drug resistance later in later life resulting in metastatic cancer growth and, ultimately, mortality. Therefore, drug resistance is a major challenge in the treatment of lung cancer (3) . It is imperative to elucidate the underlying mechanisms and identify novel strategies to overcome drug resistance.
Cisplatin, a platinum-containing anticancer drug, has been widely used for the treatment of various types of human cancer, including lung, bladder, ovarian, and head and neck cancer (4) . Cisplatin is a potent chemotherapeutic agent, however, the development of cisplatin resistance is a major obstacle for the successful treatment of lung cancer. Cisplatin resistance in lung cancer may be a result of multiple mechanisms, including excessive drug accumulation inside cancer cells, drug inactivation, enhanced repair of DNA damage, as well as abnormal activation of cell signaling pathways via growth factors and cytokines (5) . However, the precise molecular mechanisms of cisplatin resistance in lung cancer cells remains unclear.
Several studies have demonstrated the Wnt/β-catenin signaling pathway to be important in cisplatin resistance of human malignancies (6, 7) . β-catenin is highly expressed in cisplatin-resistant A549 human lung adenocarcinoma cells (A549/CDDP) (8) . Furthermore, other recent studies demonstrated that deregulation of Wnt/β-catenin signaling was closely associated with cisplatin resistance in lung cancer cells (9, 10) ; however, the underlying molecular mechanisms remain to be determined. Ding et al (11) demonstrated that β-catenin upregulates the expression of the anti-apoptotic protein B-cell β-catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl lymphoma-extra large (Bcl-xl) in CD4 + CD25 + regulatory T cells. Evasion of apoptosis is a hallmark of cancer cells and Bcl-xl has an important role in the prevention of cell apoptosis. Furthermore, cisplatin induces DNA damage, which activates the apoptotic cascade, killing cancer cells. This suggests that the β-catenin signaling pathway may promote cisplatin resistance in lung cancer cells by enhancing the expression of Bcl-xl.
The present study examined the expression of β-catenin and Bcl-xl in wild-type (A549/WT) and A549/CDDP lung adenocarcinoma cells. In addition, the functional role of the Wnt/β-catenin signaling pathway, and its association with Bcl-xl expression, were investigated in cisplatin resistance of lung adenocarcinoma cells. Cell culture and drug treatment. A549/WT and A549/CDDP cells were obtained from the Chinese Academy of Medical Sciences (Beijing, China) and the Cancer Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences (Beijing, China), respectively. Cells were cultured in RPMI-1640 culture medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (GE Healthcare Life Sciences). A549/CDDP cells were grown in complete culture medium containing 2 mg/l cisplatin. Cell cultures were maintained in a 5% CO 2 -humidified incubator at 37˚C. To activate β-catenin signaling, cells were incubated with 10 mM LiCl for 24 or 48 h.
Materials and methods

Reagents
MTS assay. An MTS assay was used to determine the proliferative potential of cells. In brief, cells were seeded onto 96-well plates at a density of 5x10 3 cells/well. Following different treatments, 20 µl of MTS solution was added to cells. After incubation for 1 h at 37˚C, the absorbance was measured at 490 nm using an Infinite M200 microplate spectrophotometer (Tecan Group Ltd., Männedorf, Switzerland). The growth inhibition rate was calculated using the following equation: Growth inhibition rate (%) = (1 -OD Sample / OD Control ) x 100. The half maximal inhibitory concentration (IC 50 ) value was calculated using the least-squares method. The IC 50 values and nonlinear regression graph were calculated using the GraphPad Prism ® (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA) by plotting the log concentration of the cisplatin versus the growth inhibition rate of cells.
Determination of apoptosis. Cellular apoptosis was evaluated using FITC Annexin V/propidium iodide (PI; BD Biosciences) double staining followed by flow cytometric analysis. Cells were treated with 0, 5 or 10 mg/l cisplatin for 24 h. Subsequently, cells were collected and resuspended in 100 µl binding buffer containing 5 µl Annexin V-FITC and 5 µl PI. After 15 min incubation in darkness at room temperature (20-25˚C), a further 400 µl of binding buffer was added to the cell suspension and the samples were analyzed by a FACScan flow cytometer (BD Biosciences).
Western blotting analysis. Total protein was extracted from cells using radioimmunoprecipitation assay lysis buffer (Cell Signaling Technology, Inc.) and the protein concentration was measured using BCA Protein Assay kit, according to manufacturer's instructions (Pierce Biotechnology, Inc., Rockford, IL, USA). Equal quantities of protein extract were separated by 10% SDS-PAGE (Sigma-Aldrich). The gel was run for 20 min at 80 V followed by 100 min at 120 V. Proteins were transferred to a polyvinylidene fluoride or nitrocellulose membrane (EMD Millipore, Billerica, MA, USA). Membranes were blocked with 5% w/v non-fat dry milk (Sigma-Aldrich) dissolved in Tris-buffered saline plus 0.1% Tween-20 (TBS-T; pH 8.3; Sigma-Aldrich) and probed with primary antibodies at 4˚C overnight. After washing with TBS-T, membranes were incubated with HRP-labeled secondary antibodies for 1-2 h at room temperature. Immunobands were detected using an enhanced chemiluminescence kit, according to manufacturer's instructions (KPL, Inc., Gaithersburg, MD, USA). The densitometric values of target proteins were analyzed by Quantity One (version 4.62; Bio-Rad Laboratories, Inc., Hercules, CA, USA) or ImageJ (version 1.48; National Institutes of Health, Bethesda, MD, USA) software.
DAPI staining and cell counting. Cells were fixed with 4% paraformaldehyde (PFA; Sigma-Aldrich) for 15 min, permeabilized in 0.1% Triton-X100 (Sigma-Aldrich) for 15 min, and stained with DAPI (1 µg/ml; Sigma-Aldrich) for 5 min in the dark. After washing with PBS, cell samples were imaged using an IX51 fluorescent microscope (Olympus Corporation, Tokyo, Japan) at x100 magnification. Three fields were randomly captured from each sample and the mean number of DAPI-positive cells was calculated.
Immunocytochemical analysis. Cells were fixed with 4% PFA for 20 min. After washing with PBS, cells were treated with PBS containing 0.5% Triton-20 (Sigma-Aldrich) for 10 min. Cell samples were blocked with PBS supplemented with 4% bovine serum albumin (Sigma-Aldrich) for 1 h at room temperature and probed with primary antibodies at 4˚C overnight or at 37˚C for 3 h. After PBS washing, samples were incubated with FITC-labeled secondary antibody for 1 h at 37˚C. The nuclei were counterstained with 5 µg/ml DAPI and the samples were visualized using confocal laser scanning microscopy (Leica TCS SP5II; Leica Microsystems GmbH, Wetzlar, Germany).
RNA interference.
To knock down β-catenin expression, A549 cells were seeded onto six-well plates at a density of 1x10 5 cells/well and maintained in 500 µl antibiotic-free culture medium. After 24 h, Lipofectamine 2000 and 33 nM siRNA diluted in 250 µl serum-and antibiotic-free culture medium were added to the cell culture. The culture medium was replaced with fresh medium 4-6 h after transfection. The sequences of siRNAs targeting β-catenin were as follows: Sense, 5'-GGA CAC AGC AGC AAU UUGU-3' and anti-sense, 5'-ACA AAU UGC UGC UGU CCTT-3'. Control cells were transfected with negative control siRNA with the following sequences: Sense, 5'-UUC UCC GAA CGU GUC ACG UTT-3' and anti-sense, 5'-ACG UGA CAC GUU CGG AGA ATT-3'.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted using an RNeasy Mini kit, according to the manufacturer's instructions (TianGen Biotech Co., Ltd.). Total RNA (2 µl) was reverse transcribed in a 20-µl reaction system using a Quant Reverse Transcriptase kit (TianGen Biotech Co., Ltd.). qPCR was performed using a 7500 Real-Time PCR system (Thermo Fisher Scientific, Inc.) and a SuperReal PreMix (SYBR Green) kit (TianGen Biotech Co., Ltd.). Primers used for qPCR amplification were as follows: Bcl-xl, forward, 5'-CCT GAA TGA CCA CCT AGA GCCTT-3' and reverse, 5'-TCA TGC CCG TCA GGA ACCAG-3'; 18S rRNA, forward, 5'-GTA ACC CGT TGA ACC CCATT-3' and reverse, 5'-CCA TCC AAT CGG TAG TAG CG-3'. The cycling conditions used were as follows: Pre-denaturation at 94˚C for 2 min; denaturation at 94˚C for 15 sec; annealing at 55˚C for 20 sec; extension at 68˚C for 35 sec. A total of 40 cycles were performed. The relative expression of Bcl-xl was normalized to 18S rRNA and was calculated using the 2 -ΔΔCq method (12) . (Fig. 1B) . To investigate the potential role of Wnt/β-catenin signaling in cisplatin resistance, the protein expression of β-catenin in A549/WT and A549/CDDP cells was determined by immunoblotting. As demonstrated in Fig. 2 , a significant upregulation of β-catenin was detected in A549/CDDP cells compared with A549/WT cells (P<0.05), suggesting that β-catenin may participate in the cisplatin resistance of lung adenocarcinoma cells.
LiCl reduces the sensitivity of A549/WT cells to cisplatin.
LiCl has previously been demonstrated to confer chemotherapy resistance in several tumor cell types, such as hepatoblastoma (13), ovarian carcinoma (14) and A549 lung cancer cells (8) . In the current study, treatment of A549/WT cells with 5 or 10 mg/l cisplatin resulted in a marked loss of cell viability, which was abolished by treatment with 10 mM LiCl (P<0.01 compared with cisplatin treatment alone; Fig. 3A and B) . Furthermore, 10 mM LiCl reduced the sensitivity of A549/WT cells to different concentrations of cisplatin. The IC 50 value of the LiCl plus cisplatin treatment group was elevated compared with that of cisplatin treatment alone (9.79±0.76 vs. 7.87±0.57 mg/l; n=3; Fig. 3C ). In addition, LiCl markedly reduced cellular apoptosis induced by cisplatin (Fig. 3D) . These results indicate that LiCl reduced the sensitivity of A549/WT cells to cisplatin, suggesting that LiCl-conferred drug resistance may be a general phenomenon in cancer cells.
LiCl treatment activates Wnt/β-catenin signaling in A549/WT cells.
To assess the molecular mechanism by which LiCl promoted cisplatin resistance in A549/WT cells, the protein expression level of total and p-β-catenin in LiCl-treated A549/WT cells was determined. As demonstrated in Fig. 4A -C, LiCl significantly increased β-catenin and p-β-catenin compared with the non-treated controls (P<0.05). In addition, LiCl treatment led to nuclear translocation of β-catenin in A549/WT cells, indicating the activation of β-catenin signaling (Fig. 4D) . These results suggest that activation of Wnt/β-catenin signaling may be one of the mechanisms by which LiCl promotes cisplatin resistance in A549/WT cells. Cells were stained with anti-β-catenin antibody (red) and nuclei were counterstained with DAPI (blue). Samples were examined using confocal laser scanning microscopy (magnification, x1,000). LiCl, lithium chloride; p-β-catenin. phosphorylated-β-catenin.
C
LiCl upregulates Bcl-xl expression in A549/WT cells. Bcl-xl is a member of the Bcl-2 protein family and functions as a pro-survival factor, inhibiting cellular apoptosis (15, 16) . As evasion of apoptosis is the key to drug resistance in cancer treatment, the current study examined the potential involvement of Bcl-xl in cisplatin resistance of lung adenocarcinoma cells in the presence and absence of LiCl. The results demonstrated that the protein expression level of Bcl-xl was significantly elevated in A549/CDDP cells compared with A549/WT cells (P<0.05; Silencing of β-catenin downregulates Bcl-xl and sensitizes A549/WT cells to cisplatin. In order to explore the potential association between Bcl-xl and β-catenin signaling pathways in cisplatin resistance of lung adenocarcinoma cells, β-catenin expression was silenced using siRNA in A549/WT cells. Transfection of siRNA targeting β-catenin efficiently downregulated the mRNA (Fig. 7A) and protein (Fig. 7B ) levels of β-catenin in A549/WT cells compared with negative control siRNA (P<0.01). Additionally, β-catenin siRNA significantly inhibited the growth of A549/WT cells (P<0.05) and caused a further reduction of cisplatin-induced growth inhibition (P<0.01; Fig. 8A and B) . Furthermore, silencing of β-catenin with siRNA decreased the inhibition rate of cisplatin, as demonstrated by MTS assay. The IC 50 value of cisplatin was reduced in cells transfected with β-catenin siRNA (β-catenin siRNA, 4.98±1.37 mg/l; control, 7.87±0.57 mg/l; negative control, 7.45±0.49 mg/l; Fig. 8C ). Furthermore, β-catenin siRNA increased cisplatin-induced apoptosis in A549/WT cells (Fig. 8D ). In accordance with a previous observation that β-catenin promoted transcription of Bcl-xl (17) , the present study observed that silencing of β-catenin in A549/WT cells significantly decreased the mRNA (P<0.001; Fig. 9A ) and protein (P<0.01; Fig. 9B and C) expression of Bcl-xl compared with negative control cells. In addition, knockdown of β-catenin reduced β-catenin phosphorylation in A549/WT cells (Fig. 9B) . These results indicate that silencing of β-catenin sensitized A549/WT cells to cisplatin and this effect may be mediated by downregulation of Bcl-xl expression.
Discussion
Cisplatin resistance is a major challenge during lung cancer treatment. The molecular mechanism of cisplatin resistance in lung cancer cells is largely unknown, therefore, there are few efficient strategies to overcome such resistance. The current study revealed the Wnt/β-catenin signaling pathway and anti-apoptotic protein Bcl-xl to be involved in cisplatin resistance of human A549 cells. These findings indicate that molecular targeting of Wnt/β-catenin signaling may sensitize lung cancer cells to cisplatin.
Platinum derivatives, such as cisplatin, are widely used chemotherapeutic agents during lung cancer treatment, however, their efficiency can be affected by a number of factors (5) . Various genes are abnormally expressed in drug resistant cancer cells, such as increased levels of anti-apoptotic genes (such as Bcl-xl, Bcl-2 and Survivin) and reduced levels of pro-apoptotic genes (such as Bax and Bcl-2-associated death promoter) (18) . In addition, multiple signaling pathways are activated during cisplatin resistance, including the Wnt/β-catenin pathway (8) (9) (10) . However, the cross-talk that occurs among these signaling pathways and mediators is still unclear.
The Wnt/β-catenin signaling pathway has been shown to be an essential signal transduction pathway in tumorigenesis and progression of various types of cancer (19, 20) . In the present study, a significant upregulation of β-catenin was observed in A549/CDDP cells compared with A549/WT cells, which is in accordance with a previous observation (8) . Furthermore, interference of β-catenin expression by siRNA suppressed cell growth and increased cisplatin sensitivity in A549/WT cells. Consistent with the findings of the current study, a previous investigation observed that downregulation of β-catenin expression reversed resistance to cisplatin in A2780 ovarian cancer cells (21) . The same in vivo study demonstrated that silencing of β-catenin inhibited the progression of ovarian cancer in mice (21) . Other studies have proposed the Wnt/β-catenin pathway as a potential therapeutic target in hepatocellular carcinoma (HCC) (22, 23) . These lines of evidence suggest that targeting Wnt/β-catenin signaling is a promising strategy for combating cisplatin resistance in lung cancer.
It is widely accepted that defects in the apoptotic pathway contribute to tumor cell survival and resistance to anticancer therapy (18) . Therefore, targeting endogenous apoptotic inhibitor proteins, such as the Bcl-2 family, is considered to be a promising strategy for the treatment of cancer and overcoming chemotherapeutic resistance (16, 24) . Bcl-xl, a member of the Bcl-2 family, is a pro-survival protein that prevents apoptosis by inhibiting the release of cytochrome c from mitochondria (15, 16) . In the present study, increased expression of Bcl-xl mRNA was detected in A549/CDDP cells and LiCl significantly elevated the mRNA and protein levels of Bcl-xl in A549/WT cells. Notably, silencing of β-catenin increased the sensitivity of A549/WT cells to cisplatin and downregulated Bcl-xl expression. These results indicate that Bcl-xl may be a critical target gene of Wnt/β-catenin signaling in cisplatin-resistant lung cancer.
β-catenin is a key component of Wnt/β-catenin signaling. Activated β-catenin translocates into the nucleus and binds to T-cell factors to regulate transcription. Accumulating evidence has suggested that tumor cells depend on β-catenin for survival and downregulation of β-catenin results in tumor cell apoptosis, which is associated with reduced levels of Bcl-xl (25) . β-catenin was identified to induce Bcl-xl expression in CD8 + T cells, whereas upregulated β-catenin reduced Bcl-xl in cultured HepG2 HCC cells (26) . This contradiction may be attributed to the varied responses and signaling mechanisms in different types of cancer cells. In addition, other members of the Bcl-2 protein family, such as Bcl-2, Bax and Bcl-2 homologous antagonist/killer, may also be involved in anticancer drug resistance regulated by Wnt/β-catenin signaling.
In summary, the present study demonstrated that A549/CDDP cells expressed high levels of β-catenin and Bcl-xl, and interference of β-catenin by siRNA enhanced cisplatin sensitivity in A549/WT cells by downregulation of Bcl-xl. The findings suggest that targeting Wnt/β-catenin signaling may be a valuable strategy for overcoming cisplatin resistance in lung cancer. Future studies should investigate the effects of β-catenin silencing in vivo using animal models of lung cancer.
